Yoon Ah Cho

Dr. Yoon Ah Cho

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
YCYoon Ah Cho
Yoon Ah Cho
HLHyunwoo Lee
Hyunwoo Lee
DKDeok Geun Kim
Deok Geun Kim
HKHyunjin Kim
Hyunjin Kim
SHSang Yun Ha
Sang Yun Ha
KKKyoung-Mee Kim
Kyoung-Mee Kim
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), microsatellite instability (MSI), and tumor mutation burden (TMB) have been proposed as a predictive biomarker to predict response to immune checkpoint blockade (ICB). We aimed to find the relationship of PD-L1 IHC to TMB and MSI using a comprehensive cancer panel assay (CCPA) with >500 genes in advanced cancer patients. CCPA results from 588 archived tissue samples were analyzed for TMB and MSI. In seven samples, whole exome sequencing confirmed TMB with Pearson’s correlation coefficient of 0.972 and all MSI-high cases were validated by pentaplex PCR. Association of TMB and MSI with their corresponding PD-L1 IHC was analyzed. The median TMB value of 588 cases was 8.25 mutations (mut)/Mb (range 0–426.8) with different distributions among the tumor types, with high proportions of high-TMB (>10mut/Mb) in tumors from melanoma, colorectal, gastric, and biliary tract. The TMB values significantly correlated with PD-L1 expression, and this correlation was prominent in gastric and biliary tract cancers. Moreover, the MSI score, the proportion of unstable MSI sites to total assessed MSI sites, showed a significant correlation with the TMB values and PD-L1 scores. This study demonstrates that PD-L1 expression is significantly associated with TMB and MSI score and this correlation depends on the location of the primary tumor.

3 October 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YCYoon Ah Cho
Yoon Ah Cho
YCYoon‐La Choi
Yoon‐La Choi
IHInwoo Hwang
Inwoo Hwang
Kyungjong LeeKyungjong Lee
Kyungjong Lee
JCJong Ho Cho
Jong Ho Cho
JHJoungho Han
Joungho Han
Background: Nuclear protein in testis (NUT) carcinoma is a rare tumor associated with NUT rearrangement that can present as poorly differentiated to undifferentiated carcinoma, with or without abrupt squamous differentiation. It is often misdiagnosed as poorly differentiated carcinoma or undifferentiated carcinoma if NUT is not suspected. In this study, we retrospectively analyzed pulmonary NUT carcinoma cases diagnosed with NUT immunohistochemical staining and discuss the differential diagnosis to provide information for this rare and aggressive entity.Methods: Cases, diagnosed as “NUT carcinoma” in lung pleura and “metastatic NUT carcinoma from the lung” in lymph nodes were diagnosed between 2017 and 2019 at the Samsung Medical Center (SMC). Clinical features such as age, sex, treatment and follow‐up period, and pathological reports were obtained by reviewing patients’ electronic medical records.Results: A total of 10 NUT carcinoma cases were found in the SMC pathology database. Seven patients were men and six were non‐smokers. Tumor cells showed various cellular features such as round, squamoid, and spindle. Some cases had initially been misdiagnosed as spindle cell neoplasm, round cell sarcoma, squamous cell carcinoma and small cell carcinoma. All cases showed diffuse strong nuclear expression of NUT immunohistochemical staining, and some were positive for p63 staining and negative for CD56 staining.Conclusions: NUT carcinoma is often misdiagnosed because of its various morphologies. It is important to consider NUT as one of the differential diagnoses when encountering lung biopsy with undifferentiated morphology.Key points: Due to various morphological features, NUT carcinoma can be misdiagnosed It is important to consider NUT carcinoma when diagnosing a poorly differentiated or undifferentiated tumor

19 April 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
YCYoon Ah Cho
Yoon Ah Cho
SKSeung Yeon Ko
Seung Yeon Ko
YSYong Joon Suh
Yong Joon Suh
SKSanghwa Kim
Sanghwa Kim
Jung Ho ParkJung Ho Park
Jung Ho Park
Mi Jung Jung KwonMi Jung Jung Kwon
Mi Jung Jung Kwon
Background: The prognostic relevance of the PIK3CA mutation together with PD-L1, c-Met, and mismatch repair deficiency (dMMR) have not been fully investigated in Asian women with breast cancer (BC) who have undergone postoperative adjuvant chemotherapy. Methods: We analyzed PIK3CA mutations via peptide nucleic acid (PNA)-mediated real-time PCR assay, PD-L1/c-Met expression via immunohistochemistry (IHC), and microsatellite instability (MSI) status using PCR and IHC, in 191 resected BCs from 2008 to 2011. The Cancer Genome Atlas (TCGA) dataset for the involvement of the PIK3CA mutation with PD-L1/c-Met/MMR was explored. Results: The PNA clamp-mediated assay was able to detect the PIK3CA mutation in 1% of the mutant population in the cell line validation. Using this method, the PIK3CA mutation was found in 78 (49.4%) of 158 samples. c-Met and PD-L1 positivity were identified in 31.4 and 21.8% of samples, respectively, which commonly correlated with high histologic grade and triple-negative subtype. MSI/dMMR was observed in 8.4% of patients, with inconsistency between MMR IHC and the MSI PCR. The PIK3CA mutation exhibited a poor prognostic association regarding recurrence-free survival (RFS) in both overall and triple-negative BCs. In subgroup analyses, the PIK3CA-mutated tumors showed poorer RFS than the PIK3CA-wildtype within the c-Met-positive, MSS, triple-negative, or age onset <50 years subgroups, which showed a similar trend of association in TCGA data. Conclusions: PIK3CA mutation together with c-Met or dMMR/MSI status might be relevant to poor prognosis in BC subsets, especially in Asian women.

12 November 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HKHyunjin Kim
Hyunjin Kim
YHY. J. Heo
Y. J. Heo
YCYoon Ah Cho
Yoon Ah Cho
SKS. Y. Kang
S. Y. Kang
SAS. Ahn
S. Ahn
KKKyoung-Mee Kim
Kyoung-Mee Kim

5 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
MKMo-Jong Kim
Mo-Jong Kim
YCYoon Ah Cho
Yoon Ah Cho
EKEunhye Kim
Eunhye Kim
JCJi-Young Choe
Ji-Young Choe
JPJi Won Park
Ji Won Park
Eun-Kyoung ChoiEun-Kyoung Choi
Eun-Kyoung Choi
The cellular prion protein (PrPC) is known to play a role in cancer proliferation and metastasis. However, the role of PrPC expression in hepatocellular carcinoma (HCC) is unknown. This study investigated whether overexpression of PrPC affects recurrence after surgical resection and survival in HCC. A total of 110 HCC patients who underwent hepatic resection were included. They were followed up for a median of 42 months (range 1–213 months) after hepatectomy. The relationships between PrPC expression and the HCC histologic features, recurrence of HCC following surgical resection, and survival of the patients were examined. Seventy-one cases (64.5%) of HCC demonstrated higher expression of PrPC. The expression of PrPC was only correlated with diabetes mellitus. There was no association between PrPC expression and age, sex, hypertension, hepatitis B virus positivity, alcohol consumption, Child–Pugh class, major portal vein invasion, serum alpha-fetoprotein, and HCC size or number. The 1-year recurrence rates in patients with higher PrPC expression were higher than those with lower PrPC expression. The cumulative survival rates of patients with higher PrPC expression were significantly shorter than those of patients with lower PrPC expression. In conclusion, PrPC expression is closely associated with early recurrence and poor survival of HCC patients following surgical resection.

23 March 2021 in Human Pathology
Verified
Journal Article
Closed access
YCYoon Ah Cho
Yoon Ah Cho
JHJiyeon Hyeon
Jiyeon Hyeon
HLHyunwoo Lee
Hyunwoo Lee
JCJunhun Cho
Junhun Cho
SKSeok-Jin Kim
Seok-Jin Kim
YKYoung Hyeh Ko
Young Hyeh Ko